KR101513181B1 - Ｌｈ 액체 제형 - Google Patents

Ｌｈ 액체 제형 Download PDF

Info

Publication number
KR101513181B1
KR101513181B1 KR1020107012131A KR20107012131A KR101513181B1 KR 101513181 B1 KR101513181 B1 KR 101513181B1 KR 1020107012131 A KR1020107012131 A KR 1020107012131A KR 20107012131 A KR20107012131 A KR 20107012131A KR 101513181 B1 KR101513181 B1 KR 101513181B1
Authority
KR
South Korea
Prior art keywords
formulation
hlh
fsh
formulations
hplc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107012131A
Other languages
English (en)
Korean (ko)
Other versions
KR20100088147A (ko
Inventor
리타 아고스티네토
파브리지오 사마리타니
알렉산드라 델 리오
조엘 리챠드
Original Assignee
메르크 세로노 에스. 에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르크 세로노 에스. 에이. filed Critical 메르크 세로노 에스. 에이.
Publication of KR20100088147A publication Critical patent/KR20100088147A/ko
Application granted granted Critical
Publication of KR101513181B1 publication Critical patent/KR101513181B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020107012131A 2007-11-01 2008-10-29 Ｌｈ 액체 제형 Active KR101513181B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07119832 2007-11-01
EP07119832.9 2007-11-01
US448107P 2007-11-28 2007-11-28
US61/004,481 2007-11-28
PCT/EP2008/064679 WO2009056569A1 (en) 2007-11-01 2008-10-29 Lh liquid formulations

Publications (2)

Publication Number Publication Date
KR20100088147A KR20100088147A (ko) 2010-08-06
KR101513181B1 true KR101513181B1 (ko) 2015-04-21

Family

ID=39167502

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107012131A Active KR101513181B1 (ko) 2007-11-01 2008-10-29 Ｌｈ 액체 제형

Country Status (25)

Country Link
US (1) US8664369B2 (https=)
EP (1) EP2219607B1 (https=)
JP (1) JP5551601B2 (https=)
KR (1) KR101513181B1 (https=)
CN (1) CN101842083B (https=)
AU (1) AU2008320844B2 (https=)
BR (1) BRPI0818324B8 (https=)
CA (1) CA2700662C (https=)
CY (1) CY1113121T1 (https=)
DK (1) DK2219607T3 (https=)
EA (1) EA019432B1 (https=)
EC (1) ECSP10010224A (https=)
ES (1) ES2393233T3 (https=)
HR (1) HRP20120660T1 (https=)
IL (1) IL205105A (https=)
MX (1) MX2010004639A (https=)
MY (1) MY153976A (https=)
NZ (1) NZ583991A (https=)
PL (1) PL2219607T3 (https=)
PT (1) PT2219607E (https=)
RS (1) RS52566B (https=)
SI (1) SI2219607T1 (https=)
UA (1) UA101484C2 (https=)
WO (1) WO2009056569A1 (https=)
ZA (1) ZA201001907B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102007143B (zh) 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 具有超延迟时效特征的新型胰岛素衍生物
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
JP2011001273A (ja) * 2009-06-16 2011-01-06 Eci Inc ｅＭＩＰを有効成分とする水溶性製剤
PL2451437T3 (pl) * 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
RU2553375C2 (ru) * 2010-02-12 2015-06-10 Интас Биофармасьютикалс Лимитед Жидкий состав фолликулостимулирующего гормона
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN102293756A (zh) * 2011-08-24 2011-12-28 蚌埠丰原涂山制药有限公司 一种尿促性素冻干粉针剂及其制备方法
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
JP2016505601A (ja) * 2012-12-26 2016-02-25 ウォックハート リミテッド 医薬組成物
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
CN105960249B (zh) 2014-01-09 2021-03-16 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
JP6723921B2 (ja) 2014-01-09 2020-07-15 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
US9895423B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224896A1 (en) 2003-03-28 2004-11-11 Nyu Medical Center STQ peptides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
IT1250075B (it) * 1991-12-18 1995-03-30 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti gonadotropine.
US5681302A (en) * 1994-06-14 1997-10-28 Minnesota Mining And Manufacturing Company Elastic sheet-like composite
WO1996029095A1 (en) * 1995-03-21 1996-09-26 Applied Research Systems Ars Holding N.V. Hcg liquid formulations
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
CN1309567A (zh) * 1998-07-23 2001-08-22 伊莱利利公司 Fsh和fsh变体制剂,产品和方法
DE602004019761D1 (de) * 2003-01-08 2009-04-16 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
CA2518903C (en) * 2003-04-02 2013-02-05 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224896A1 (en) 2003-03-28 2004-11-11 Nyu Medical Center STQ peptides

Also Published As

Publication number Publication date
EA019432B1 (ru) 2014-03-31
HRP20120660T1 (hr) 2012-09-30
AU2008320844A1 (en) 2009-05-07
ZA201001907B (en) 2011-05-25
JP5551601B2 (ja) 2014-07-16
BRPI0818324B1 (pt) 2019-12-24
KR20100088147A (ko) 2010-08-06
CA2700662C (en) 2015-10-13
ECSP10010224A (es) 2010-07-30
CA2700662A1 (en) 2009-05-07
EP2219607B1 (en) 2012-08-15
RS52566B (sr) 2013-04-30
ES2393233T3 (es) 2012-12-19
IL205105A0 (en) 2010-11-30
UA101484C2 (en) 2013-04-10
MX2010004639A (es) 2010-08-04
SI2219607T1 (sl) 2012-09-28
US20100261649A1 (en) 2010-10-14
NZ583991A (en) 2012-02-24
US8664369B2 (en) 2014-03-04
WO2009056569A1 (en) 2009-05-07
BRPI0818324A2 (pt) 2017-05-16
MY153976A (en) 2015-04-30
HK1145443A1 (en) 2011-04-21
PT2219607E (pt) 2012-08-31
EP2219607A1 (en) 2010-08-25
IL205105A (en) 2015-04-30
JP2011502968A (ja) 2011-01-27
CY1113121T1 (el) 2016-04-13
DK2219607T3 (da) 2013-06-17
AU2008320844B2 (en) 2013-08-29
PL2219607T3 (pl) 2012-12-31
CN101842083B (zh) 2012-11-14
CN101842083A (zh) 2010-09-22
EA201070549A1 (ru) 2010-10-29
WO2009056569A9 (en) 2010-01-21
BRPI0818324B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
KR101513181B1 (ko) Ｌｈ 액체 제형
KR101662631B1 (ko) Ｆｓｈ의 액체 포뮬레이션
JP4699991B2 (ja) 非イオン性界面活性剤を一緒に伴うｆｓｈ及びｌｈの液体医薬組成物
CN100488566C (zh) Fsh和lh以及非离子表面活性剂的液体药物制剂
HK1145443B (en) Lh liquid formulations
HK40013805A (en) Liquid formulation of fsh
HK1149494B (en) Liquid formulation of fsh

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20180329

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20190328

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20200330

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20210402

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20220323

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 12